This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Salti, G. I. Articles by Das Gupta, T. K. Search for Related Content PubMed PubMed Citation Articles by Salti, G. I. Articles by Das Gupta, T. K.

Micropthalmia Transcription Factor: A New Prognostic Marker in Intermediate-thickness Cutaneous Malignant Melanoma¹

Departments of Surgical Oncology [G. I. S., T. M., A. S., T. K. D. G.] and Pathology [M. F.], College of Medicine, and Department of Mathematics, Statistics, and Computer Sciences [D. M.], University of Illinois at Chicago, Chicago, Illinois 60612

Micropthalmia transcription factor (Mitf) is involved in melanocyte development and differentiation. The current study was undertaken to determine whether there is a relationship between Mitf expression and survival in patients with intermediate-thickness (1.0–4.0 mm) melanoma. Original paraffin blocks or slides of the primary tumor were accessible in 63 such patients. Mitf expression was evaluated by immunocytochemistry and analyzed visually. Slides were graded as follows according to the percentage of cells whose nuclei stained positive for Mitf: (a) 0, 0%; (b) +1, 1–25%; (c) +2, 26–50%; (d) +3, 51–75%; and (e) +4, >75%. Median follow-up was 50 months. Mean thickness was 2.2 ± 0.7 mm. Mean overall survival was 171.90 ± 13.12 months. Mean disease-free survival was 168.53 ± 13.96 months. Fifty-two melanomas (82.5%) stained positive for Mitf. By univariate analysis, mean overall survival and disease-free survival in patients whose melanomas did not express Mitf were 80.89 ± 17.98 months (median, 51 months) and 71.36 ± 19.87 months (median, 40 months), respectively. This compares with 187.90 ± 13.41 months (median, not reached) and 186.78 ± 13.84 months (median, not reached), respectively, for patients whose melanomas expressed Mitf (P = 0.0086 and P = 0.0054). These findings persisted in multivariate analysis. In addition, patients with >50% Mitf expression had significantly fewer nodal metastases after node dissection than patients with 50% Mitf expression (P = 0.04). Our data suggest that Mitf may be a new molecular prognostic marker in patients with intermediate-thickness melanoma.

This article has been cited by other articles:

				S. Ugurel, R. Houben, D. Schrama, H. Voigt, M. Zapatka, D. Schadendorf, E. B. Brocker, and J. C. Becker Microphthalmia-Associated Transcription Factor Gene Amplification in Metastatic Melanoma Is a Prognostic Marker for Patient Survival, But Not a Predictive Marker for Chemosensitivity and Chemotherapy Response Clin. Cancer Res., November 1, 2007; 13(21): 6344 - 6350. [Abstract] [Full Text] [PDF]

				A. J. Miller and M. C. Mihm Jr. Melanoma. N. Engl. J. Med., July 6, 2006; 355(1): 51 - 65. [Full Text] [PDF]

				C. Petti, A. Molla, C. Vegetti, S. Ferrone, A. Anichini, and M. Sensi Coexpression of NRASQ61R and BRAFV600E in Human Melanoma Cells Activates Senescence and Increases Susceptibility to Cell-Mediated Cytotoxicity. Cancer Res., July 1, 2006; 66(13): 6503 - 6511. [Abstract] [Full Text] [PDF]

				K. Koyanagi, S. J. O'Day, R. Gonzalez, K. Lewis, W. A. Robinson, T. T. Amatruda, C. Kuo, H.-J. Wang, R. Milford, D. L. Morton, et al. Microphthalmia Transcription Factor as a Molecular Marker for Circulating Tumor Cell Detection in Blood of Melanoma Patients Clin. Cancer Res., February 15, 2006; 12(4): 1137 - 1143. [Abstract] [Full Text] [PDF]

				C. Wellbrock and R. Marais Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation J. Cell Biol., August 29, 2005; 170(5): 703 - 708. [Abstract] [Full Text] [PDF]

				W.-Y. Yue and Z.-P. Chen Does Vasculogenic Mimicry Exist in Astrocytoma? J. Histochem. Cytochem., August 1, 2005; 53(8): 997 - 1002. [Abstract] [Full Text] [PDF]

				A. J. Miller, J. Du, S. Rowan, C. L. Hershey, H. R. Widlund, and D. E. Fisher Transcriptional Regulation of the Melanoma Prognostic Marker Melastatin (TRPM1) by MITF in Melanocytes and Melanoma Cancer Res., January 15, 2004; 64(2): 509 - 516. [Abstract] [Full Text] [PDF]

				C. K. Chang, I. A. Jacobs, V. M. Vizgirda, and G. I. Salti Melanoma in the Elderly Patient Arch Surg, October 1, 2003; 138(10): 1135 - 1138. [Abstract] [Full Text] [PDF]

				J. Du, A. J. Miller, H. R. Widlund, M. A. Horstmann, S. Ramaswamy, and D. E. Fisher MLANA/MART1 and SILV/PMEL17/GP100 Are Transcriptionally Regulated by MITF in Melanocytes and Melanoma Am. J. Pathol., July 1, 2003; 163(1): 333 - 343. [Abstract] [Full Text] [PDF]

				H. R. Widlund, M. A. Horstmann, E. R. Price, J. Cui, S. L. Lessnick, M. Wu, X. He, and D. E. Fisher {beta}-Catenin-induced melanoma growth requires the downstream target Microphthalmia-associated transcription factor J. Cell Biol., September 16, 2002; 158(6): 1079 - 1087. [Abstract] [Full Text] [PDF]

				X. Chen, A. J. Maniotis, D. Majumdar, J. Pe'er, and R. Folberg Uveal Melanoma Cell Staining for CD34 and Assessment of Tumor Vascularity Invest. Ophthalmol. Vis. Sci., August 1, 2002; 43(8): 2533 - 2539. [Abstract] [Full Text] [PDF]

				E. Selzer, V. Wacheck, T. Lucas, E. Heere-Ress, M. Wu, K. N. Weilbaecher, W. Schlegel, P. Valent, F. Wrba, H. Pehamberger, et al. The Melanocyte-specific Isoform of the Microphthalmia Transcription Factor Affects the Phenotype of Human Melanoma Cancer Res., April 1, 2002; 62(7): 2098 - 2103. [Abstract] [Full Text] [PDF]

				G. I. Salti, A. Kansagra, M. A. Warso, S. G. Ronan, and T. K. Das Gupta Clinical Node-Negative Thick Melanoma Arch Surg, March 1, 2002; 137(3): 291 - 295. [Abstract] [Full Text] [PDF]

				J. Du and D. E. Fisher Identification of Aim-1 as the underwhite Mouse Mutant and Its Transcriptional Regulation by MITF J. Biol. Chem., January 4, 2002; 277(1): 402 - 406. [Abstract] [Full Text]